Genetic, Ethnic, and Gender Differences in the Pharmacokinetics of Antiretroviral Agents

Overview

Journal Curr HIV/AIDS Rep

Publisher Current Science

Specialty Infectious Diseases

Date 2006 Sep 15

PMID 16970838

Citations 14

Authors

Margalida Rotger

Chantal Csajka

Amalio Telenti

Affiliations

Soon will be listed here.

Abstract

Variable antiretroviral therapy (ART) drug response likely reflects the combined influence of environment, underlying disease, concurrent drugs, and genetics. Gender exerts modest or negligible effects on ART disposition, and it is expected to have limited clinical implication, although it should be accounted for in large population studies. Ethnic denominations have, with the notable exception of efavirenz, no clear influence on ART disposition. Exploration of genetic factors might offer a better comprehension to the largely unpredictable and unresolved variability in ART concentrations and related toxicity or treatment outcome. Despite the negative perception of genetic research among the general public, this type of investigation is now widely accepted by concerned parties: patients, relatives, and study volunteers.

Citing Articles

A Meta-Analytic Review of the Effect of Antiretroviral Therapy on Neurocognitive Outcomes in Adults Living with HIV-1 in Low-and Middle-Income Countries.

Michael H, Youbi E, Ohadoma S, Ramlall S, Oosthuizen F, Polyakova M Neuropsychol Rev. 2021; 32(4):828-854.

PMID: 34757490 DOI: 10.1007/s11065-021-09527-y.

Geographic differences in gut microbiota composition impact susceptibility to enteric infection.

Porras A, Shi Q, Zhou H, Callahan R, Montenegro-Bethancourt G, Solomons N Cell Rep. 2021; 36(4):109457.

PMID: 34320343 PMC: 8333197. DOI: 10.1016/j.celrep.2021.109457.

Exploring the Engagement of Racial and Ethnic Minorities in HIV Treatment and Vaccine Clinical Trials: A Scoping Review of Literature and Implications for Future Research.

Bauerle Bass S, DAvanzo P, Alhajji M, Ventriglia N, Trainor A, Maurer L AIDS Patient Care STDS. 2020; 34(9):399-416.

PMID: 32931317 PMC: 10722429. DOI: 10.1089/apc.2020.0008.

Efavirenz and Metabolites in Cerebrospinal Fluid: Relationship with CYP2B6 c.516G→T Genotype and Perturbed Blood-Brain Barrier Due to Tuberculous Meningitis.

Nightingale S, Chau T, Fisher M, Nelson M, Winston A, Else L Antimicrob Agents Chemother. 2016; 60(8):4511-8.

PMID: 27161633 PMC: 4958147. DOI: 10.1128/AAC.00280-16.

Superior Effects of Antiretroviral Treatment among Men Who have Sex with Men Compared to Other HIV At-Risk Populations in a Large Cohort Study in Hunan, China.

Su S, Chen X, Mao L, He J, Wei X, Jing J Int J Environ Res Public Health. 2016; 13(3).

PMID: 27005640 PMC: 4808946. DOI: 10.3390/ijerph13030283.

References

Jullien V, Treluyer J, Rey E, Jaffray P, Krivine A, Moachon L . Population pharmacokinetics of tenofovir in human immunodeficiency virus-infected patients taking highly active antiretroviral therapy. Antimicrob Agents Chemother. 2005; 49(8):3361-6. PMC: 1196246. DOI: 10.1128/AAC.49.8.3361-3366.2005. View

Mould D, Zhang X, Nieforth K, Salgo M, Buss N, Patel I . Population pharmacokinetics and exposure-response relationship of enfuvirtide in treatment-experienced human immunodeficiency virus type 1-infected patients. Clin Pharmacol Ther. 2005; 77(6):515-28. DOI: 10.1016/j.clpt.2005.02.005. View

Zhou H, Adedoyin A, Wilkinson G . Differences in plasma binding of drugs between Caucasians and Chinese subjects. Clin Pharmacol Ther. 1990; 48(1):10-7. DOI: 10.1038/clpt.1990.111. View

de Maat M, Huitema A, Mulder J, Meenhorst P, van Gorp E, Beijnen J . Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals. Br J Clin Pharmacol. 2002; 54(4):378-85. PMC: 1874435. DOI: 10.1046/j.1365-2125.2002.01657.x. View

Pfister M, Labbe L, Hammer S, Mellors J, Bennett K, Rosenkranz S . Population pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother. 2002; 47(1):130-7. PMC: 148981. DOI: 10.1128/AAC.47.1.130-137.2003. View

Fletcher C, Jiang H, Brundage R, Acosta E, Haubrich R, Katzenstein D . Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis. 2004; 189(7):1176-84. DOI: 10.1086/382754. View

Haas D, Smeaton L, Shafer R, Robbins G, Morse G, Labbe L . Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study. J Infect Dis. 2005; 192(11):1931-42. DOI: 10.1086/497610. View

Crommentuyn K, Kappelhoff B, Mulder J, Mairuhu A, van Gorp E, Meenhorst P . Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol. 2005; 60(4):378-89. PMC: 1884825. DOI: 10.1111/j.1365-2125.2005.02455.x. View

Brendel K, Legrand M, Taburet A, Baron G, Goujard C, Mentre F . Population pharmacokinetic analysis of indinavir in HIV-infected patient treated with a stable antiretroviral therapy. Fundam Clin Pharmacol. 2005; 19(3):373-83. DOI: 10.1111/j.1472-8206.2005.00315.x. View

10.

Pfister M, Labbe L, Lu J, Hammer S, Mellors J, Bennett K . Effect of coadministration of nelfinavir, indinavir, and saquinavir on the pharmacokinetics of amprenavir. Clin Pharmacol Ther. 2002; 72(2):133-41. DOI: 10.1067/mcp.2002.126183. View

11.

Jackson K, Rosenbaum S, Kerr B, Pithavala Y, Yuen G, Dudley M . A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial. Antimicrob Agents Chemother. 2000; 44(7):1832-7. PMC: 89969. DOI: 10.1128/AAC.44.7.1832-1837.2000. View

12.

Chen D, Rosenstein D, Muthappan P, Hilsenbeck S, Miller F, Emanuel E . Research with stored biological samples: what do research participants want?. Arch Intern Med. 2005; 165(6):652-5. DOI: 10.1001/archinte.165.6.652. View

13.

Kappelhoff B, van Leth F, MacGregor T, Lange J, Beijnen J, Huitema A . Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther. 2005; 10(1):145-55. View

14.

Haas D, Ribaudo H, Kim R, Tierney C, Wilkinson G, Gulick R . Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS. 2004; 18(18):2391-400. View

15.

Pai M, Schriever C, Diaz-Linares M, Novak R, Rodvold K . Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1. Pharmacotherapy. 2004; 24(5):592-9. DOI: 10.1592/phco.24.6.592.34744. View

16.

Ioannidis J, Ntzani E, Trikalinos T . 'Racial' differences in genetic effects for complex diseases. Nat Genet. 2004; 36(12):1312-8. DOI: 10.1038/ng1474. View

17.

Wang J, Sonnerborg A, Rane A, Josephson F, Lundgren S, Stahle L . Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz. Pharmacogenet Genomics. 2006; 16(3):191-8. DOI: 10.1097/01.fpc.0000189797.03845.90. View

18.

Wilson J, Weale M, Smith A, Gratrix F, Fletcher B, Thomas M . Population genetic structure of variable drug response. Nat Genet. 2001; 29(3):265-9. DOI: 10.1038/ng761. View

19.

Burger D, van der Heiden I, Porte C, van der Ende M, Groeneveld P, Richter C . Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol. 2006; 61(2):148-54. PMC: 1885008. DOI: 10.1111/j.1365-2125.2005.02536.x. View

20.

Saito S, Iida A, Sekine A, Miura Y, Ogawa C, Kawauchi S . Identification of 779 genetic variations in eight genes encoding members of the ATP-binding cassette, subfamily C (ABCC/MRP/CFTR. J Hum Genet. 2002; 47(4):147-71. DOI: 10.1007/s100380200018. View